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Purpose: Both intrathecal sufentanil (ITS) and intrathecal 
morphine (ITM) improve analgesia in obstetrical or cardiac 
procedures. From a pharmacokinetic standpoint, combining 
these two opioids may improve perioperative analgesia. We 
performed a prospective randomized double-blind study to 
compare the analgesic efficacy of ITM alone vs a mixture of 
a low dose of ITS plus ITM for perioperative pain relief in 
colorectal surgery. 
Methods: Eighty adult patients undergoing colorectal surgery 
were randomly allocated to receive either 0.4 mg ITM alone 
or 10 µg ITS plus 0.4 mg ITM before general anesthesia. 
Intraoperative intravenous sufentanil consumption, postopera-
tive morphine consumption delivered with a patient controlled 
analgesia device, pain scores, patient satisfaction and adverse 
effects were recorded for the first 48 hr postoperatively. 
Results: No differences were observed between groups with 
respect to intraoperative sufentanil consumption (39 ± 23 µg in 
group ITM and 40 ± 25 µg in group ITS plus ITM, P = 0.85) and 
in postoperative morphine consumption in postanesthesia care 
unit (6 ± 5 mg vs 6 ± 5 mg, P = 0.59), at 24 hr (26 ± 17 vs 24 
± 15 mg, P = 0.59) and at 48 hr (47 ± 31 vs 44 ± 22 mg, P = 
0.58). Similarly, no differences were observed in regards to pain 
relief, patient satisfaction and incidence of adverse effects. 
Conclusions: These results do not support the addition of 
10 µg ITS to 0.4 mg ITM for colorectal surgery, as low dose 
sufentanil does not improve intraoperative and postoperative 
analgesia in this setting.
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Objectif : Le sufentanil intrathécal (ITS) et la morphine intrathécale 
(ITM) améliorent tous deux l’analgésie lors de procédures 
obstétricales ou cardiaques. D’un point de vue pharmacocinétique, 
la combinaison de ces deux opiacés pourrait améliorer l’analgésie 
périopératoire. Nous avons mené une étude prospective randomisée 
en double aveugle afin de comparer l’efficacité analgésique de 
l’ITM seule vs un mélange d’une faible dose d’ITS ajoutée à l’ITM 
pour le soulagement de la douleur périopératoire lors de chirurgie 
colorectale.
Méthode : Quatre-vingts patients adultes subissant une chirurgie 
colorectale ont été randomisés à recevoir soit 0,4 mg ITM seule 
ou 10 µg ITS plus 0,4 mg ITM avant l’anesthésie générale. 
La consommation peropératoire de sufentanil intraveineux, la 
consommation postopératoire de morphine libérée par un appareil 
d’analgésie contrôlée par le patient, les scores de douleur, la 
satisfaction des patients ainsi que les effets secondaires ont été 
enregistrés durant les 48 premières heures postopératoires.
Résultats : Aucune différence n’a été observée entre les groupes 
concernant la consommation peropératoire de sufentanil (39 ± 23 
µg groupe ITM et 40 ± 25 µg groupe ITS plus ITM, P = 0,85) ou 
la consommation postopératoire de morphine dans l’unité de soins 
post-anesthésiques (6 ± 5 mg vs 6 ± 5 mg, P = 0,59), à 24 h 
(26 ± 17 vs 24 ± 15 mg, P = 0,59) et à 48 h (47 ± 31 vs 44 ± 
22 mg, P = 0,58). De même, aucune différence n’a été observée 
quant au soulagement de la douleur, de la satisfaction des patients 
et de l’incidence d’effets secondaires.
Conclusion : Ces résultats ne soutiennent pas l’addition de 10 µg 
ITS à 0,4 mg ITM pour la chirurgie colorectale, étant donné que le 
sufentanil à faible dose n’améliore pas l’analgésie peropératoire et 
postopératoire dans ce contexte.
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P
ERIOPERATIVE pain control with intrathe-
cal (IT) opioid administration has been used 
successfully in a variety of surgical specialties.1 
Intrathecal morphine (ITM), in particular, is 
a simple and reliable way of providing effective anal-
gesia after cardiovascular,2 thoracic,3 obstetric4 and 
orthopedic procedures.5 In major abdominal surgery, 
ITM (0.3–0.4 mg) combined with patient controlled 
analgesia (PCA) improves perioperative analgesia com-
pared to PCA alone during the first 24 hr after sur-
gery.6,7 Intrathecal morphine has the advantage of 
providing long-lasting analgesia after a single injection. 
However, because morphine is a hydrophilic opioid, its 
peak analgesic effect is delayed (six to seven hours after 
injection) and its rostral spread carries the risk of late 
respiratory depression especially at high doses.1,8 
Sufentanil, on the other hand, is a lipophilic opioid. 
Therefore, intrathecal sufentanil (ITS) has a very fast 
onset (five to ten minutes) and is relatively short lived 
(two to four hours).1 Its analgesic efficacy at low-doses 
(2.5–10 µg) combined to a local anesthetic is well doc-
umented in obstetrics where it improves analgesia dur-
ing labour and intraoperative Cesarean delivery.9–13 In 
abdominal surgery, sufentanil is usually administered 
epidurally or intravenously14,15 and the clinical experi-
ence in non-vascular major abdominal surgery with 
ITS is still limited. A recent study in major abdominal 
surgery showed that a large dose of ITS (150 µg) was 
able to blunt the intraoperative stress response and 
produced effective analgesia, but was associated with 
prolonged mechanical ventilation.16
Combining ITS and ITM may provide the optimal 
analgesic regimen to cover the intraoperative, the 
immediate, and the delayed postoperative periods 
up to 24 hr.3 This combination of IT opiods has 
been studied in cardiac,2,17 abdominal aortic18 and 
thoracic3,19 surgery to shorten the onset of morphine 
and to reduce ITM dose. However, the doses of ITS 
used in these studies were relatively high (25–50 µg) 
to achieve adequate pain relief. In colorectal surgery, 
lower doses of ITS, similar to those used in obstetrics,4 
might be sufficient to provide adequate intraoperative 
analgesia. Therefore, we hypothesized that a combina-
tion of ITS 10 µg and ITM 0.4 mg compared to ITM 
0.4 mg alone, would improve the perioperative pain 
control of patients undergoing colorectal surgery. We 
designed and conducted this prospective randomized 
double-blind study to test our hypothesis.
Methods
The study was approved by our institution Ethics 
Committee, and written informed consent was 
obtained from all patients before participation. Eighty 
adult patients ASA I–III, from 18 to 80 yr of age, 
scheduled for elective colorectal surgery were included. 
Patients with neurological disorders, an active infec-
tion, receiving opioid therapy for chronic pain, or with 
abnormal coagulation tests, were excluded. Using a 
computer generated randomization patients were allo-
cated to one of two groups. Group M, received 0.4 
mg preservative-free morphine (2 mL) plus 2 mL 0.9% 
saline intrathecally; Group SM received 10 µg sufent-
anil (2 mL) plus 0.4 mg preservative-free morphine (2 
mL) intrathecally. The volume of each study solution 
was 4 mL and was prepared in an adjacent room by an 
anesthesiologist who took no further part in the study. 
Treatment allocation was kept concealed in numbered 
envelopes that were opened consecutively after patient 
recruitment. 
On the day before surgery, all patients were 
instructed on how to use a PCA device (CADD-
Legacy 6300™, Smiths Medical MD, Inc., St. Paul, 
MN, USA) and a visual analogue scale (VAS) to evalu-
ate pain. The scale consisted of an unmarked 100-mm 
line (0-mm = no pain and 100-mm = worst pain 
imaginable). A similar tool was used to assess patient 
satisfaction.
One hour before surgery, patients were premedi-
cated with oral midazolam 7.5 mg. Upon arrival in the 
operating room, standard monitoring was instituted 
(electrocardiogram, non-invasive blood pressure and 
pulse oximetry) and a peripheral intravenous catheter 
was inserted. Patients were then placed in the lateral 
position. Spinal puncture was performed at the L3–L4 
or L4–L5 interspace with a 25-G pencil point spinal 
needle and the study solution was injected into the 
subarachnoid space. The anesthesiologist who per-
formed the IT injection and managed the patient 
intraoperatively was not involved in postoperative 
care or data collection. Both patients and observers 
were blinded. After the IT injection, general anes-
thesia was induced with propofol 2–3 mg·kg–1 iv and 
sufentanil 0.2 µg·kg–1 iv. Rocuronium 0.6 mg·kg–1 iv 
was administered to facilitate endotracheal intubation. 
Anesthesia was maintained with a mixture of air-oxy-
gen (50%–50%) and desflurane. Heart rate, peripheral 
oxygen saturation (SaO2), fractional inspired oxygen 
concentration, fractional expired carbon dioxide con-
centration and fractional expired desflurane (FeDES) 
concentration were controlled continuously. Arterial 
pressure was measured every five minutes. Surgery 
started 45 to 60 min after IT injection. 
Using a two-step approach, the anesthetic depth 
was adjusted as required by clinical conditions to 
maintain heart rate and blood pressure within pre-
defined limits. First, FeDES was increased up to 7% 
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(low fresh gas flow was maintained) followed by sup-
plemental intravenous sufentanil (10 µg) only if the 
pulse rate and/or the mean arterial pressure rose 30% 
above resting values. Rocuronium increments 10–20 
mg iv were used to facilitate abdominal surgery. At 
the end of the surgery, patients were awakened, their 
tracheas were extubated, and they were transferred 
in the postanesthesia care unit (PACU). Cessation of 
anesthetic agents was standardized. The time from 
end of surgery to extubation was recorded. 
When sufficiently awake, patients were asked to 
grade their pain using the VAS. If required (VAS ≥ 
30) initial titration of intravenous morphine with 
boluses of 2 mg was started every five to ten minutes 
until VAS was below 30. At that point, the intrave-
nous PCA was started and the patient was encouraged 
to use it when analgesia was deemed necessary. A stan-
dard PCA program was used throughout the study 
period: morphine solution 1 mg·mL–1, morphine 
bolus 1 mg, lock-out five minutes, maximal dose of 
40 mg of morphine over four hours, no background 
infusion. In addition, all patients received intrave-
nous paracetamol every six hours during the first 48 
hr. Rescue analgesia (ketorolac 30 mg iv every eight 
hours) was given when the pain score at rest remained 
≥ 30 on VAS. Patient satisfaction was assessed at 24 
and 48 hr using the VAS.20 Pain scores at rest and 
coughing were recorded every six hours during the 
whole study period. Data recording was done by an 
independent observer who was unaware of treatment 
allocation. 
At our institution, all patients who receive more 
than 300 µg of ITM are continuously monitored in 
PACU for a 24-hr period. If respiratory rate was < 8 
breaths·min–1 and and/or SaO2 < 95%, the PCA was 
stopped and naloxone 40 µg was given intravenously 
if deemed necessary. Sedation was evaluated in PACU 
and on the ward using a five-point scale (1 = awake 
and alert; 2 = sedated, responds to verbal stimulus; 
3 = sedated; responds to mild physical stimulus; 4 
= sedated, responds to moderate or strong physical 
stimulus; and 5 = not arousable). Nausea and vomit-
ing were treated with dehydrobenzperidol 0.625 mg 
iv. Adverse effects (respiratory depression, pruritus, 
nausea and vomiting) were continuously recorded for 
the first 24 hr and then every six hours up to 48 hr. 
Foley catheters were routinely used for the first 24 
hr. Occurrence of urinary retention was monitored 
thereafter.
The primary endpoints were the intraoperative 
consumption of sufentanil, morphine consumption at 
24 hr and 48 hr and the pain at rest and on coughing, 
recorded on the VAS. Secondary endpoints included 
use of rescue analgesia, patient satisfaction and inci-
dence of adverse effects.
Sample size calculation was performed a priori 
based on the anticipated intraoperative intravenous 
sufentanil reduction. Drawing from a previous study 
which showed a 23% reduction in intraoperative intra-
venous sufentanil consumption,3 we estimated that 
34 patients per group would be required to detect a 
significant difference with an α risk set at 5% and a β 
risk at 20%. Allowing for attrition, we recruited 40 
patients per group. Normal distribution of variables 
was confirmed using the Kolmogorov-Smirnov test. 
Statistical analysis was performed using unpaired 
Student’s t test for comparison of duration of surgery, 
and consumption of intravenous sufentanil and time 
from end of surgery to extubation. Visual analogue 
scale for pain relief and patient satisfaction, as well as 
postoperative morphine consumption at 24 hr and 48 
hr were compared over time with a repeated measure 
ANOVA. Frequency data were analyzed with the χ2 
or the Fisher exact tests. Data are presented as mean 
± SD and ranges. Statistics were performed using a 
standard statistical package (SPSS 11.0, SPSS Inc., 
Chicago, IL, USA). A P value < 0.05 was considered 
significant.
Results
Eighty patients participated in the study (40 per 
group). Two patients in group M had severe nau-
sea and the PCA device had to be discontinued in 
the postoperative period. Data derived from these 
two patients were taken into account for analysis of 
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TABLE I  Patient characteristics and type and duration of 
surgery
   Group M Group SM
   (n = 38) (n = 39)
Analyzed patients (male:female) 38 (21:17) 39 (18:21)
Weight (kg)  70 ± 14 72 ± 13
Height (cm)  170 ± 12 168 ± 10
ASA 1/2/3  6/22/9 9/25/5
Duration of surgery (min) 210 ± 72 196 ± 90
Time to extubation (min) 10 ± 9 10 ± 8
Colorectal surgery
 Anterior resections 13 12
 Sigmoidectomy 6 5
 Colectomy
  right 8 9
  left 10 13
Values are means ± SD, or number of patients. There was no 
significant difference between the two groups. Group M = intra-
thecal morphine group; Group SM = intrathecal sufentanil and 
morphine.
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the intraoperative period but were excluded for the 
postoperative period. In group SM, one patient was 
excluded because of failure to perform lumbar punc-
ture. A total of 77 patients were therefore prospec-
tively assessed over 48 hr: 38 and 39 in groups M and 
SM respectively. 
Patient characteristics, type and duration of sur-
gery, and time to extubation were similar between the 
two groups (Table I). Total intraoperative intravenous 
sufentanil was 39 ± 23 µg in group M and 40 ± 25 µg 
in group SM (P = 0.85). Figure 1 details the evolu-
tion of intraoperative administration of intravenous 
sufentanil. Overall perioperative morphine consump-
tion is illustrated in Figure 2. Total intravenous mor-
phine titrated in the PACU was 6 ± 5 (0–18) and 6 
± 5 mg (0–20) in group M and SM respectively (P 
= 0.59). Cumulative morphine consumption during 
the first 24 hr was 26 ± 17 (1–50) and 24 ± 15 mg 
(7–50) in group M and SM respectively (P = 0.59). 
Corresponding doses during the first 48 hr were 47 
± 31 (1–134) and 44 ± 22 mg (9–83) respectively (P 
= 0.58). In group M, eight patients (21%) received 
rescue analgesia during the first 24 hr and three (8%) 
during the following 24 hr compared to 11 (28%) and 
five (13%) in group SM (P = 0.71).
Visual analogue scale pain scores at rest or on 
coughing (measured every six hours) and patient sat-
isfaction did not differ at any time point between the 
groups during the first 48-hr study period (Table II). 
No patient had a sedation score at 5. One patient in 
group M and two patients in group SM had a sedation 
score of 4 (Table III). The incidence of nausea, vomit-
ing and pruritus were similar between the two groups 
FIGURE 1  Cumulative intravenous sufentanil requirements 
during surgery. There was no significant difference between 
groups. Data are mean ± SD. 0 = start of surgery.
FIGURE 2  Cumulative intravenous morphine consump-
tion in the PACU during the first 24 hr and 48 hr after 
surgery. Black and white bars represent M and SM groups 
respectively. There was no significant difference between 
groups. Data represent mean ± SD. PACU = postanesthesia 
care unit.
TABLE II  Visual analogue scale pain scores at rest and 
with coughing, and patient satisfaction during the first 48 
hr after surgery
 Group M Group SM
 (n = 38) (n = 39)
Pain score in PACU (0-100 mm) 48 ± 30 40 ± 31
Pain score at rest at 24 hr (0-100 mm) 18 ± 12 21 ± 19
Pain score on cough at 24 hr (0-100 mm) 67 ± 27 63 ± 20
Pain score at rest at 48 hr (0-100 mm) 21 ± 9 14 ± 15
Pain score on cough at 48 hr (0-100 mm) 58 ± 21 42 ± 17
Satisfaction at 24 hr (0-100 mm) 81 ± 16 83 ± 11
Satisfaction at 48 hr (0-100 mm) 72 ± 14 81 ± 13
Values are means ± SD, or number of patients. There were no 
significant differences between the two groups. PACU = postan-
esthetic care unit; Group M = intrathecal morphine; Group SM = 
intrathecal sufentanil and morphine.
TABLE III  Postoperative adverse effects during the first 
48 hr after surgery
 Group M Group SM
 (n = 38) (n = 39)
PONV 16 14
Pruritus 10 12
Sedation score > 3  1 2
Values are number of patients. There was no significant difference 
between the two groups. PONV = postoperative nausea and vom-
iting; Group M = intrathecal morphine; Group SM = intrathecal 
sufentanil and morphine.
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(Table III). No patient required prolonged mechani-
cal ventilation, no respiratory depression occurred and 
no urinary retention was observed.
Discussion
Our study shows that the combination of ITS 10 
µg and ITM 0.4 mg does not provide a substantial 
clinical benefit compared to ITM 0.4 mg alone when 
administered in a double-blind randomized design 
for colorectal surgery. This statement is supported 
by the absence of significant differences between the 
two groups in each of the three primary endpoints: 
intraoperative consumption of intravenous sufentanil, 
immediate and delayed postoperative intravenous 
morphine consumption, and pain scores during the 
first 48 hr after surgery.
Our study investigates the theoretical advantages of 
combining ITS and ITM over ITM alone for colorectal 
surgery. Combining the two opioids may provide an 
optimal analgesic regimen to cover analgesic require-
ments for the first 24 hr.1 Previous studies that have 
demonstrated the benefit of intravenous opioids in 
abdominal surgery have either compared ITS to intra-
venous morphine PCA,16 ITM to intravenous morphine 
PCA,7 or a combination of ITS and ITM to intravenous 
morphine PCA.18 We decided to conduct this prospec-
tive study using doses of ITM and ITS based on experi-
ence gained in different surgical settings.12,21
Despite these theoretical arguments, our research 
hypothesis was not confirmed by our results. This 
study was powered to detect a sparing effect on intra-
operative intravenous sufentanil consumption based 
on Liu’s et al. study.3 However, the main difference is 
that we used a smaller dose of ITS compared to Liu’s 
report (10 vs 50 µg). We chose this dose based on two 
arguments. First, low-doses of IT lipophilic opiods 
such as fentanyl or sufentanil provide rapid and effec-
tive analgesia during labour.1,13 In addition, low doses 
of ITS (2.5–10 µg) combined with a local anesthetic 
hasten the onset of block, and improve intraoperative 
and postoperative analgesia for two to five hours after 
Cesarean delivery.1,13 Our second argument to opt for 
this ITS dosage was based on a study conducted by Lu 
et al.22 investigating the dose response of ITS (12.5, 
25, or 50 µg) in young adult female volunteers. The 
authors observed patients’ response to lower extrem-
ity pain and concluded that doses larger than 12.5 µg 
did not improve the speed of onset, magnitude, or 
duration of analgesia but only produced a dose-related 
increase in side effects (nausea, vomiting and respira-
tory depression). In addition, higher doses resulted 
in higher serum sufentanil concentrations, which may 
further aggravate respiratory depression.
We performed a post-hoc power analysis to test for 
a possible ß-type error. Assuming that the highest dif-
ference that we observed in intraoperative intravenous 
sufentanil consumption (at 60 min: 30 µg ± 17 µg vs 
25 µg ± 11 µg in group M and SM respectively) would 
persist, 124 patients per group would be needed to 
demonstrate a significant difference. Although sig-
nificant, such an opioid sparing effect (i.e., 5 µg of 
intravenous sufentanil) would be of small magnitude 
and thus of limited clinical relevance.
It is possible, however that we opted for an 
insufficient dose of ITS. Nociceptive stimuli during 
colorectal surgery may involve different pain path-
ways including neuro-humoral and immunological 
responses, sympathetic and pituitary-adreno-cortical 
axis activation which may differ from those observed 
in obstetric, orthopedic or vascular surgery.23 In 
fact, large doses of ITS (150 µg) have been shown 
to partially blunt the stress response and to reduce 
postoperative cumulative intravenous morphine con-
sumption.16 However, there are controversies about 
the neurotoxicity of large doses of ITS. Rawal et al.,24 
have shown in a sheep model that doses of 150 to 
240 µg ITS were associated with histopathological 
changes. On the other hand, Sabbe et al.,25 showed 
no evidence of neurotoxicity [cerebrospinal fluid 
(CSF) and histopathologic analyses] after several daily 
injections of 5, 25, or 50 µg ITS in a dog model. It 
is therefore reasonable to think that ITS doses should 
not exceed 50 µg. One can argue that 10 µg ITS was 
insufficient in our study, but the combination of 50 
µg ITS and 0.5 mg ITM were not superior to ITM 
alone in thoracic surgery, even though this study was 
probably underpowered (ten patients per group).3 
Again, it is possible that a ceiling effect similar to 
the one observed in volunteers22 or in the obstetrical 
setting21 may also exist for ITS. A properly powered 
dose-response study investigating ITS combinations 
to ITM in colorectal surgery could answer this ques-
tion. However, according to our results the expected 
clinical benefits are likely to be minor. 
Another explanation can be advanced to explain 
our negative results. Lipophilic properties of sufent-
anil result in a rapid clearance from the CSF towards 
plasma after IT administration.26 Hansdottir et al.,27 
administered 15 µg of ITS and observed that the peak 
plasma concentration of sufentanil appeared after 39 
min and that the mean residence time in CSF was 55 
min. The rapid pharmacokinetics of sufentanil explain 
its rapid onset of action and short-lasting effects. As in 
our study the beginning of surgery started 30 to 45 
min after the IT injection, it is possible that the CSF 
sufentanil concentration was insufficient to provide 
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analgesia at the start of surgery. It is therefore not 
surprising that the analgesic effect of ITS did not last 
into the postoperative period. 
Despite the lack of effectiveness of ITS, its use in 
association with ITM did not increase the incidence 
of adverse effects. In particular, we did not observe 
significantly delayed extubation times. This may be 
related to a precise stepwise protocol, avoiding any 
overdosage of intravenous sufentanil, and our routine 
practice to extubate all patients in the operating room. 
Such institutional practices may greatly influence extu-
bation times as illustrated by Devys et al.’s7 results. 
Their study was conducted in France where patients 
are routinely extubated in the PACU and even though 
they used doses of ITM similar to ours, mean times 
to extubation were 50 min in the control group (no 
ITM) and 39 min in the group receiving ITM.
Although we did not observe any respiratory 
depression, we stress the fact that 400 µg of ITM 
may be excessive at institutions unable to provide 
overnight monitoring of patients. This dose is higher 
than the current recommendation for common surgi-
cal procedures.5,28,29 However, in contrast to ortho-
pedic or obstetrical procedures, the optimal dose of 
ITM for major abdominal surgery has not yet been 
determined, although others have successfully used 
ITM doses in the range that we have studied.6,7 It is 
possible that had we used a lower dose of ITM, then 
the analgesic benefit of ITS may have been unveiled. 
Although this combination may appear attractive at 
institutions unable to closely monitor patients over-
night, this hypothesis needs to be formally tested.
We conclude that in spite of the rationale for com-
bining a lipophilic with an hydrophilic opioid, there is 
no evidence that a low dose ITS added to ITM short-
ens onset of morphine and improves perioperative 
analgesia in colorectal surgery. As discussed above, 
the duration of analgesia may be enhanced with larger 
doses of ITS. However, since previous studies have 
suggested that higher dosages of ITS may be neuro-
toxic and that a ceiling effect may exist, the expected 
benefits of such IT opioid combinations compared to 
morphine alone are likely to be minor and probably 
not clinically relevant in this setting. Therefore, we 
believe that further studies investigating the effective-
ness of higher ITS dosages combined with ITM in 
colorectal surgery may be designed in a dose-response 
pattern within non-toxic ITS dosage ranges.
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